Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m(−2) (D) with the combination of docetaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacilio, C, Morabito, A, Nuzzo, F, Gravina, A, Labonia, V, Landi, G, Rossi, E, De Maio, E, Di Maio, M, D'aiuto, G, Botti, G, Normanno, N, Chiodini, P, Gallo, C, Perrone, F, de Matteis, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361414/
https://www.ncbi.nlm.nih.gov/pubmed/16622454
http://dx.doi.org/10.1038/sj.bjc.6603096
Descripción
Sumario:The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m(−2) (D) with the combination of docetaxel 80 mg m(−2) and epirubicin 75 mg m(−2) (ED). The response rate (72 vs 79%), the progression-free survival (median 9 vs 11 months) and the overall survival (median 18 vs 21 months) were not significantly different between the ED (n=26) and D arms (n=25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy.

Ejemplares similares